Promarker®D vs. Standard of Care: A New Era in Kidney Disease Prediction

Discover Why Promarker®D Is Advancing Beyond the Traditional Approach

Chronic kidney disease (CKD) remains a growing global health burden, especially among individuals with type 2 diabetes. Yet for many, progression to kidney damage occurs silently — often undetected until it’s too late for meaningful intervention. The standard of care (SOC), relying heavily on eGFR and albuminuria, has long served as the clinical foundation for assessing kidney function. But what if we could do better?

Promarker®D is an innovative blood test designed to predict diabetic kidney disease (DKD) up to four years in advance, even in patients who currently show no signs of kidney impairment. Using a proprietary algorithm and a unique panel of protein biomarkers, PromarkerD shifts kidney care from reactive to proactive — giving clinicians a powerful new tool to identify at-risk patients before traditional tests reveal a problem.

What This Comparative Paper Covers

Here's what you'll learn:

  • A clinical performance comparison of PromarkerD, eGFR, and albuminuria
  • The science behind PromarkerD’s predictive biomarkers
  • How PromarkerD enables early detection years before functional decline
  • Implications for patient stratification, treatment planning, and resource optimization
  • Opportunities to reduce unnecessary interventions and healthcare costs

Whether you’re a clinician, researcher, healthcare executive, or policymaker, this paper provides valuable context for understanding the emerging role of predictive diagnostics in chronic kidney disease management.

Download the White Paper: PromarkerD vs. Standard of Care

Access the full comparison to explore how PromarkerD stacks up against traditional methods — and what it means for the future of kidney care.
Complete the form to receive your copy of the PromarkerD vs. Standard of Care White Paper.
Start making more informed, data-driven decisions today.

Scroll to Top